Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Preferred Stock Liabilities (2017 - 2018)

Crinetics Pharmaceuticals has reported Preferred Stock Liabilities over the past 2 years, most recently at $93.0 million for Q2 2018.

  • Quarterly results put Preferred Stock Liabilities at $93.0 million for Q2 2018, changed N/A from a year ago — trailing twelve months through Jun 2018 was $93.0 million (changed N/A YoY), and the annual figure for FY2017 was $29.7 million, up 67.42%.
  • Preferred Stock Liabilities for Q2 2018 was $93.0 million at Crinetics Pharmaceuticals, up from $29.7 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for CRNX hit a ceiling of $93.0 million in Q2 2018 and a floor of $29.7 million in Q4 2017.